TRIARYL METHANE COMPOUND FOR SICKLE CELL DISEASE

• Main Authors: BELLOT EMILE M JR, MOUSSA ADEL M, HAIDAR REEM M, SUN MINGHUA, HALPERIN JOSE, KELLEHER EUGENE W, FROIMOWITZ MARK, TAFT HEATHER N, GAO YING-DUO, KHER FALGUNI M, BRUGNARA CARLO, LOMBARDY RICHARD J, CLIFFORD JOHN J, SACHDEVA YESH P
• Format: Patent
• Language: English
• Published: 04.09.2008
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. SOLUTION: The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups are replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle cell dehydration and/or delay the occurrence of erythrocyte sickling or deformation. COPYRIGHT: (C)2008,JPO&INPIT